Literature DB >> 27867026

Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Cecilia Shi Ni Loo1, Nelson Siu Kei Lam1, Deying Yu1, Xin-Zhuan Su2, Fangli Lu3.   

Abstract

Parasitic protozoan diseases continue to rank among the world's greatest global health problems, which are also common among poor populations. Currently available drugs for treatment present drawbacks, urging the need for more effective, safer, and cheaper drugs. Artemisinin (ART) and its derivatives are some of the most important classes of antimalarial agents originally derived from Artemisia annua L. However, besides the outstanding antimalarial and antischistosomal activities, ART and its derivatives also possess activities against other parasitic protozoa. In this paper we review the activities of ART and its derivatives against protozoan parasites in vitro and in vivo, including Leishmania spp., Trypanosoma spp., Toxoplasma gondii, Neospora caninum, Eimeria tenella, Acanthamoeba castellanii, Naegleria fowleri, Cryptosporidium parvum, Giardia lamblia, and Babesia spp. We conclude that ART and its derivatives may be good alternatives for treating other non-malarial protozoan infections in developing countries, although more studies are necessary before they can be applied clinically.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiprotozoan activity; Artemisinin; Leishmania spp; Neospora caninum; Toxoplasma gondii; Trypanosoma spp

Mesh:

Substances:

Year:  2016        PMID: 27867026      PMCID: PMC5316320          DOI: 10.1016/j.phrs.2016.11.012

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  92 in total

1.  Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.

Authors:  Yuliya V Mishina; Sanjeev Krishna; Richard K Haynes; John C Meade
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

2.  In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.

Authors:  A Giacometti; O Cirioni; G Scalise
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

Review 3.  New approaches from nanomedicine for treating leishmaniasis.

Authors:  Víctor Gutiérrez; Amedea B Seabra; Rosa M Reguera; Jayant Khandare; Marcelo Calderón
Journal:  Chem Soc Rev       Date:  2016-01-07       Impact factor: 54.564

Review 4.  Human toxoplasmosis-Searching for novel chemotherapeutics.

Authors:  Magdalena Antczak; Katarzyna Dzitko; Henryka Długońska
Journal:  Biomed Pharmacother       Date:  2016-06-13       Impact factor: 6.529

5.  Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.

Authors:  S Abgrall; C Rabaud; D Costagliola
Journal:  Clin Infect Dis       Date:  2001-10-10       Impact factor: 9.079

Review 6.  Trimethoprim-sulfamethoxazole revisited.

Authors:  Philip A Masters; Thomas A O'Bryan; John Zurlo; Debra Q Miller; Nirmal Joshi
Journal:  Arch Intern Med       Date:  2003-02-24

7.  Interaction of ferriprotoporphyrin IX with the antimalarials amodiaquine and halofantrine.

Authors:  G Blauer
Journal:  Biochem Int       Date:  1988-10

Review 8.  Current drug therapy and pharmaceutical challenges for Chagas disease.

Authors:  José Bermudez; Carolina Davies; Analía Simonazzi; Juan Pablo Real; Santiago Palma
Journal:  Acta Trop       Date:  2015-12-30       Impact factor: 3.112

Review 9.  Leishmaniasis: current status of available drugs and new potential drug targets.

Authors:  Nisha Singh; Manish Kumar; Rakesh Kumar Singh
Journal:  Asian Pac J Trop Med       Date:  2012-06       Impact factor: 1.226

10.  Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse model.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Vera Manser; Ho Ning Wong; Richard K Haynes; Andrew Hemphill
Journal:  Vet Res       Date:  2016-02-17       Impact factor: 3.683

View more
  23 in total

1.  Untargeted LC-MS metabolomic studies of Asteraceae species to discover inhibitors of Leishmania major dihydroorotate dehydrogenase.

Authors:  Lucas A Chibli; Annylory L Rosa; Maria Cristina Nonato; Fernando B Da Costa
Journal:  Metabolomics       Date:  2019-04-04       Impact factor: 4.290

Review 2.  Toxoplasma gondii and schizophrenia: a review of published RCTs.

Authors:  Sam D Chorlton
Journal:  Parasitol Res       Date:  2017-05-15       Impact factor: 2.289

3.  Dihydroartemisinin, an active metabolite of artemisinin, interferes with Leishmania braziliensis mitochondrial bioenergetics and survival.

Authors:  Nathalia Grazzia; Sinésio Boaventura; Vera Lucia Garcia; Fernanda R Gadelha; Danilo C Miguel
Journal:  Parasitol Res       Date:  2021-01-08       Impact factor: 2.289

Review 4.  Synthetic biology, combinatorial biosynthesis, and chemo‑enzymatic synthesis of isoprenoids.

Authors:  Alexandra A Malico; Miles A Calzini; Anuran K Gayen; Gavin J Williams
Journal:  J Ind Microbiol Biotechnol       Date:  2020-09-03       Impact factor: 3.346

Review 5.  Potential applications of artemisinins in ocular diseases.

Authors:  Bing-Wen Lu; Li-Ke Xie
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

6.  Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: A possible link.

Authors:  Gerald Geroldinger; Matthias Tonner; Judith Quirgst; Martin Walter; Sritama De Sarkar; Laura Machín; Lianet Monzote; Klaus Stolze; J Catharina Duvigneau; Katrin Staniek; Mitali Chatterjee; Lars Gille
Journal:  Biochem Pharmacol       Date:  2019-11-29       Impact factor: 5.858

7.  1,2,4-Trioxolane and 1,2,4,5-Tetraoxane Endoperoxides against Old-World Leishmania Parasites: In Vitro Activity and Mode of Action.

Authors:  Andreia Mendes; Ana Armada; Lília I L Cabral; Patrícia S M Amado; Lenea Campino; Maria L S Cristiano; Sofia Cortes
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-03

Review 8.  Design of Drug Delivery Systems Containing Artemisinin and Its Derivatives.

Authors:  Blessing Atim Aderibigbe
Journal:  Molecules       Date:  2017-02-20       Impact factor: 4.411

9.  Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.

Authors:  Leonardo J M Carvalho; Bunduurem Tuvshintulga; Arifin B Nugraha; Thillaiampalam Sivakumar; Naoaki Yokoyama
Journal:  Parasit Vectors       Date:  2020-07-20       Impact factor: 3.876

Review 10.  Artemisia annua, a Traditional Plant Brought to Light.

Authors:  Axelle Septembre-Malaterre; Mahary Lalarizo Rakoto; Claude Marodon; Yosra Bedoui; Jessica Nakab; Elisabeth Simon; Ludovic Hoarau; Stephane Savriama; Dominique Strasberg; Pascale Guiraud; Jimmy Selambarom; Philippe Gasque
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.